This is a working overview of Freeze-thaw, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilised cake or flake |
| Solubility class | Soluble in water and aqueous buffer | Also soluble in some polar organic solvents |
| Typical storage temperature | Minus 20 degrees Celsius or below | Desiccated and protected from light |
| Typical analytical method | LC-MS/MS | Reversed-phase separation with mass detection |
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
TDL Group recorded $1.48 billion in sales in 2005. Tim Hortons also operates locations on Canadian and American university campuses, including Brock University, Durham College, Georgian College, Algonquin College, Canisius College, York University, Toronto Metropolitan University, University at Buffalo, SUNY Plattsburgh, University of British Columbia, Memorial University of Newfoundland, University of Western Ontario, and Simon Fraser University. In March 2010, Tim Hortons announced further expansion on both sides of the Canada–US border to be completed by 2013. The plan called for 600 new stores in Canada (primarily in Quebec and Western Canada but also including smaller communities) and 300 new stores in the U.S. (primarily in its existing markets of Michigan, New York, and Ohio). It also called for expansion into such non-standard store locations as hospitals, universities, and airports, as well as extending its co-branding initiative with U.S. ice cream chain Cold Stone Creamery, which began in 2009, to cover 60 Canadian stores and 25 to 35 new and existing U.S. stores. It also included testing a new café/bake shop concept in at least 10 existing U.S. locations, including "enhanced finishes, fixtures, and seating areas" as well as an expansion of menu offerings. In 2010, Tim Hortons opened what were then its northernmost locations: three kiosks at NorthMart stores in Iqaluit, Nunavut. This expanded Tim Hortons' presence in every province and territory of Canada.
Pot roast – in one of the Lakota legends recorded in Lakota mythology, the character Wohpe is seen creating a dish in exactly the same manner as we make pot roasts today—sealing a large chunk of meat and vegetables in a bag and steaming it in a pot.
== Origins == In 1927, Sakel, who had recently qualified as a medical doctor in Vienna and was working in a psychiatric clinic in Berlin, began to use low (sub-coma) doses of insulin to treat drug addicts and psychotics, and when one of the patients experienced improved mental clarity after having slipped into an accidental coma, Sakel reasoned the treatment might work for mentally ill patients. Having returned to Vienna, he treated schizophrenic patients with larger doses of insulin in order to deliberately produce coma and sometimes convulsions. Sakel made his results public in 1933, and his methods were soon taken up by other psychiatrists. Joseph Wortis, after seeing Sakel practice it in 1935, introduced it to the US. British psychiatrists from the Board of Control visited Vienna in 1935 and 1936, and by 1938, 31 hospitals in England and Wales had insulin treatment units. In 1936, Sakel moved to New York and promoted the use of insulin coma treatment in US psychiatric hospitals. By the late 1940s, the majority of psychiatric hospitals in the US were using insulin coma treatment.
== Mechanism == A stock BCA solution contains the following ingredients in a highly alkaline solution with a pH 11.25: bicinchoninic acid, sodium carbonate, sodium bicarbonate, sodium tartrate, and copper(II) sulfate pentahydrate. The BCA assay primarily relies on two reactions. First, the peptide bonds in protein reduce Cu2+ ions from the copper(II) sulfate to Cu1+ (a temperature dependent reaction). The amount of Cu2+ reduced is proportional to the amount of protein present in the solution. Next, two molecules of bicinchoninic acid chelate with each Cu1+ ion, forming a purple-colored complex that strongly absorbs light at a wavelength of 562 nm. The bicinchoninic acid Cu1+ complex is influenced in protein samples by the presence of cysteine/cystine, tyrosine, and tryptophan side chains. At higher temperatures (37 to 60 °C), peptide bonds assist in the formation of the reaction complex. Incubating the BCA assay at higher temperatures is recommended as a way to increase assay sensitivity while minimizing the variances caused by unequal amino acid composition. The amount of protein present in a solution can be quantified by measuring the absorption spectra and comparing with protein solutions of known concentration.
Sources: en.wikipedia.org
The molecular evolution of vampire bat venom highlights the dominant contributions of Draculin and DSPA to its anticoagulant and proteolytic functions. Transcriptomic and proteomic data from the submaxillary glands of Desmodus rotundus show active expression of Draculin at both the RNA level and the corresponding protein production level. Venom secretion, containing Draculin and the desmoteplase salivary plasminogen activator DSPA, enables vampire bats to sustain a hawmatophagous lifestyle by disrupting the prey's normal physiological and biochemical responses during feeding. Vampire bats frequently revisit the same host for repeated feedings, and typically relick the wound for approximately 30 minutes per fe feeding, prolonging exposure of host tissues to salivary components. The parasitic nature of vampire bat feeding, coupled with the extensive application of saliva to the wound and the antigenic properties of the anticoagulants, can trigger an acquired immune response in the bat's prey. Although prey animals have been known to develop acquired immunological resistance to Draculin over prolonged exposure, the frequent site-directed or focul [sic?] mutagenesis with the venom limits the rapid evolution of such resistance.
thiol 1. Any of a class of organosulfur compounds consisting of a sulfur atom attached to a hydrogen atom and any other organic substituent, with the general formula R–SH. Thiols are the sulfur analogues of alcohols. Also thiol derivative and mercaptan. 2. The –SH functional group itself. Also sulfhydryl, sulfanyl, and mercapto.
In medical terminology, in situ belongs to a group of two-word Latin expressions, including in vitro ('within the glass', e.g., laboratory experiments), in vivo ('within the living', e.g., experiments on living organisms), and ex vivo ('out of the living', e.g., experiments on extracted tissues). These expressions facilitate concise communication of experimental and clinical contexts, much like abbreviations. In situ is widely used in medicine to describe phenomena or processes occurring in their original location. Its applications span oncology, measurement acquisition, medical simulation, and anatomical examination. Because of its versatility across such varied uses, one study has described in situ as among the most productive Latin expressions in contemporary medical discourse.
Sources: en.wikipedia.org
=== 2017: Two Masters titles, world No. 3 === During the 2017 season, Zverev greatly improved his results at the higher level tournaments on the ATP Tour except for the four major events. It was at this time Zverev, who had been using his nickname Sascha, stated in a postmatch interview with Pam Shriver, that he would no longer be referred to as Sascha. Zverev stated that only his close family can refer to him as Sascha, as he was born in Germany and identifies as a German, and does not want a Russian nickname to be used for his professional career. At the Australian Open, Zverev again pushed Rafael Nadal to the brink, but ultimately lost in five sets. His next ATP tournament was the Open Sud de France, where he won both the singles and doubles events. He and his brother defeated Fabrice Martin and Daniel Nestor for Alexander's first doubles title. The following month, he made his first Masters quarterfinal at the Miami Open, upsetting No. 3 Stan Wawrinka along the way. Nick Kyrgios defeated him at both Masters events that month. After a slow start to the clay court season, Zverev won two more titles in May, the first of which came at home in Germany at the Bavarian International Tennis Championships. He then followed up a second Masters quarterfinal at the Madrid Open with his first Masters title at the Rome Masters. He defeated Novak Djokovic in the final to become the youngest Masters champion since Djokovic in 2007 and the first such champion born in the 1990s. With the title, he also entered the top 10 for the first time.
Matched up against Poundstone in the Atlas Stones in a 'winner-take-all' scenario, Pudzianowski managed to beat his American rival by the narrowest of margins to become the first and still only man to win five World's Strongest Man titles. He competed in the 2009 World's Strongest Man competition the following year in Malta, trying to win a remarkable sixth title in 8 years. He eventually placed second after Žydrūnas Savickas returned to the competition to win the title for the first time. Following the competition, Pudzianowski said in an interview that he would not continue participating in strongman events, because of his career in Mixed Martial Arts, which required totally different training to strongman.
The circulatory system consists of the heart and blood vessels (arteries, veins and capillaries). The heart propels the circulation of the blood, which serves as a "transportation system" to transfer oxygen, fuel, nutrients, waste products, immune cells and signaling molecules (i.e. hormones) from one part of the body to another. Paths of blood circulation within the human body can be divided into two circuits: the pulmonary circuit, which pumps blood to the lungs to receive oxygen and leave carbon dioxide, and the systemic circuit, which carries blood from the heart off to the rest of the body. The blood consists of fluid that carries cells in the circulation, including some that move from tissue to blood vessels and back, as well as the spleen and bone marrow.
Opponents of seed oils have argued that linoleic acid, an essential fatty acid found in seed oils such as safflower oil and sunflower oil increases chronic disease risk such as cardiovascular disease, cancer and systemic inflammation. This idea is not supported by data from recent clinical trials or long-term epidemiological studies. It has been shown that higher in vivo circulating and tissue levels of linoleic acid are associated with lower risk of major cardiovascular events. A 2025 review of human outcome data concluded that linoleic acid from seed oils does not increase chronic disease risk. The review also noted that the human research evidence shows that linoleic acid intake does not affect inflammation or increase inflammatory biomarkers. The World Cancer Research Fund and Cancer Council Australia have stated that there is no scientific evidence that consuming seed oils increases cancer risk.
Sources: en.wikipedia.org
Mass spectrometry combined with liquid chromatography provides both molecular weight confirmation and a measure of related impurities. Tandem mass spectrometry adds sequence information. A purity percentage reported without a mass measurement does not confirm what the material is.
No. Lyophilisation slows degradation rather than stopping it, and the rate depends on residual moisture, temperature and light exposure. Freezer storage extends useful life but does not make the material permanent.
A certificate is only as good as its traceability to a specific batch and a named laboratory. Documents lacking batch numbers, method descriptions or laboratory identifiers carry little weight. Confirming what was actually received generally requires a separate test of the material in hand.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.